Richard Norton's death shows peptide hype needs a doctor, not a hashtag

What do you call a health trend that is marketed like a skincare serum, discussed like a gym tip and can still end in anaphylaxis? A medical product, whatever the packaging says. That is the uncomfortable point of the Richard Norton case.

What the coroner found

Norton, the Melbourne-based actor, martial artist and stuntman, died in March 2025 at 75. In findings released on October 28, Victorian Coroner David Ryan concluded that his death came from complications linked to two unapproved peptide products, one of them CJC-1295, according to Yahoo's report. Other outlets describe a severe allergic reaction that led to cardiac arrest, and say he had injected double the prescribed amount.

7News reports that it is believed to be the first known fatality from unapproved peptides in Australia. ABC reports that the coroner recommended the country's regulator, the TGA, consider tougher restrictions.

The "double dose" is the least interesting part

It is tempting to read this as a story about one man who took too much. We think that reading is too comfortable. Self-injection puts dosing, storage and timing in the hands of the person holding the needle, and the whole culture around peptides pushes that way. The reports we have seen don't say how Norton obtained or was guided on his products, so we won't guess. But the pattern is easy to see in the wider market.

In New Zealand, RNZ spoke to users who bought peptides through social media contacts. One said the seller sent the wrong needles, which she called "really dangerous" because it would be "so easy to give yourself way more than what you should be having." A lab owner who tested imported samples found one sample contained an unknown peptide, and vials of retatrutide labeled 10 milligrams held different amounts. When the label is a guess, a "prescribed dose" is a fragile idea.

The hype is running years ahead of the evidence

The market doesn't seem bothered. According to a BGNES report citing National Geographic, the global peptide market is projected to grow from $4.1 billion in 2025 to $11.2 billion by 2035. Meanwhile, the same report says a 2026 review of BPC-157 found just three studies with 30 participants in total, and rated the evidence as very low quality.

Jordan Glenn of SuppCo put it better than we could: "The hype surrounding these substances almost always runs ahead of the science." On TikTok, the same report notes, users promote "peptide stacking," injecting several substances at once, even though experts say no clinical studies confirm that combinations work.

That is the real product being sold, in our view: not a molecule, but a feeling of control. Sleep better, heal faster, feel years younger, all with a small pen and a protocol. Celebrity culture, we suspect, makes it worse, because a famous face can turn a risky experiment into aspirational wellness. We should be careful here. Nothing we have found suggests Norton was promoting anything, and he shouldn't be turned into a poster child for a movement he may never have joined. His death matters as a reminder of what can go wrong, not as a verdict on who he was.

Supervision is not a magic word

The tidy conclusion would be "just get a doctor involved." That is better advice than buying from a stranger, and specialists quoted in the BGNES piece recommend consulting a doctor and sticking to methods with proven effectiveness. But the Norton findings complicate it. If a prescribed dose can still be exceeded, and a severe reaction can still happen, then supervision has to mean more than a signature. It means checking what is actually being injected, explaining the risks, and monitoring the patient afterward.

That is why the coroner's push toward regulatory review seems sensible to us. It is also why a headline in The Columbian, "Kennedy to allow access to unapproved peptide injections," deserves close attention. We only have the headline, not the article, so we won't characterize the policy. But if access to unapproved peptides is loosening anywhere while a coroner is asking for tighter rules, the gap between the marketing and the safety net is getting wider.

Our verdict

Peptides are not all villains: some are established medicines, and the research on others is simply thin. The problem is the leap from "interesting in a lab" to "stack it at home." Our advice is simple. If a product is unapproved, treat it as an experiment, not a lifestyle choice. If a clinician is involved, ask what the product is, where it comes from, and what the dose limit and warning signs are. And if the main argument for something is that your friend looks amazing, remember that the friend's results are not a safety trial.

Norton's death should not become a morality tale about vanity. It should end the idea that injectable biohacking is a harmless accessory. Wellness can be fun. A needle should come with adults in the room.